66th ASH Annual Meeting: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA

Symposia: Allogeneic Transplantation: Disease Response and Comparative Treatment Studies Oral and Poster Abstracts
Oral

Research, Clinical trials, Hodgkin lymphoma, MDS, Lymphoid Leukemias, ALL, Acute Myeloid Malignancies, AML, Adult, Clinical Practice (Health Services and Quality), Non-Hodgkin lymphoma, Clinical Research, Health outcomes research, B Cell lymphoma, CML, T Cell lymphoma, Health disparities research, Chronic Myeloid Malignancies, Supportive Care, Indolent lymphoma, Diseases, Real-world evidence, Treatment Considerations, Biological therapies, Aggressive lymphoma, Immunotherapy, Registries, Lymphoid Malignancies, Survivorship, Myeloid Malignancies, Study Population, Human, Transplantation (Allogeneic and Autologous)

Room 6A (San Diego Convention Center)

Moderators:

Hongtao Liu, MD, PhD, and James LaBelle, MD, PhD, The University of Chicago Medicine

Disclosures:

Liu: Incyte: Consultancy, Other: Advisory board meeting; Rigel: Consultancy, Other: Advisory board meeting; AbbVie: Consultancy.

In this section, we have focused on clinical research aimed at improving donor and graft selection. The studies include optimizing donor selection using new molecular techniques, comparing outcomes between MMUD and MUD, investigating whether the probability of finding an 8/8 MUD affects prognosis, examining the impact of Orca-T infusion on post-transplant outcomes, and conducting an RCT comparing peripheral blood plus cord blood or bone marrow in Haplo-HSCT. Through this section, we hope clinicians can choose the most suitable donors and grafts from the currently available multiple donor options for each patient.

4:30 PM

691

T-Cell Monitoring for the Recently Expanded Repertoire of HLA Class I-Restricted Minor Histocompatibility Antigens Using Barcoded Peptide-MHC Multimers

Kyra J. Fuchs¹^*, Marcus Göransson²^*, Michel G.D. Kester³^*, Natasja W. Ettienne²^*, Marian van de Meent¹^*, Rob C.M. de Jong¹^*, Eva A.S. Koster, MD¹^*, Constantijn J.M. Halkes, MD¹^*, Ferenc A. Scheeren⁴^*, Mirjam H.M. Heemskerk, PhD¹^*, Peter Van Balen, MD¹, J.H. Frederik Falkenburg, MD, PhD¹, Sine R. Hadrup²^* and Marieke Griffioen, PhD¹^*

¹Hematology, Leiden University Medical Center, Leiden, Netherlands
²Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark
³Leiden University Medical Center, Leiden, Netherlands
⁴Dermatology, Leiden University Medical Center, Leiden, Netherlands

4:45 PM

692

Immunopeptidome Divergence between Mismatched HLA Haplotypes and Survival after Haploidentical HCT: A Retrospective Study from the CIBMTR

Pietro Crivello, PhD¹^*, Meilun He, MPH²^*, Tao Wang, PhD^3,4^*, Shahinaz M. Gadalla, MD, PhD⁵, Esteban Arrieta-Bolanos⁶^*, Steven GE Marsh, BSc, ARCS, PhD, FRCPath^7,8^*, Stephanie Lee, MD, MPH^4,9, Yung-Tsi Bolon, PhD²^* and Katharina Fleischhauer, MD^1,10^*

¹Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany
²CIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN
³Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
⁴CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
⁵Division of Cancer Epidemiology and Genetics, NCI, Rockville, MD
⁶Institute for Experimental Cellular Therapy, Essen University Hospital, Essen, Germany
⁷Anthony Nolan Research Institute, London, United Kingdom
⁸UCL Cancer Institute, London, United Kingdom
⁹Fred Hutchinson Cancer Center, Seattle, WA
¹⁰German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Essen, Germany

5:00 PM

693

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Giorgia Battipaglia^1,2^*, Allain Thibeault Ferhat Berland³^*, Jaques-Emmanuel Galimard⁴^*, Myriam Labopin^5,6,7^*, Didier Blaise, MD⁸^*, Jan Vydra, MD, PhD⁹^*, Claude-Éric Bulabois, MD¹⁰^*, Alexander Kulagin, MD, PhD¹¹^*, Franca Fagioli, MD, PhD¹²^*, Thomas Schroeder¹³^*, Igor Wolfgang Blau, MD, PhD¹⁴^*, Nicolaus Kröger, MD¹⁵^*, Urpu Salmenniemi, MD¹⁶^*, Laimonas Griskevicius¹⁷^*, Annalisa Ruggeri, MD, PhD¹⁸^*, Simona Piemontese¹⁹^*, Jaime Sanz²⁰^*, Ali Bazarbachi, MD, PhD²¹, Arnon Nagler, MD²², Eolia Brissot⁵, Mohamad Mohty, MD, PhD^23,24 and Fabio Ciceri, MD²⁵^*

¹Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy, Naples, ITA
²Federico II University of Naples, Hematology Department, Naples, Italy, Naples, Italy
³EBMT Paris study office, Paris, France
⁴EBMT Lymphoma Working Party, Paris, France
⁵Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France, Paris, France
⁶EBMT Paris office, Paris, France
⁷Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France, Paris, France
⁸Programme de Transplantation & Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Marseille, France
⁹Institute of Haematology and Blood Transfusion, Prague, Czech Republic
¹⁰Hematology Department, Grenoble University Hospital, Grenoble, France
¹¹RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation
¹²Ospedale Infantile Regina Margherita, Torino, Italy, Torino, Italy
¹³Dept. of Hematology and Stem Cell Transplantation West German Cancer Centre University Hospital Essen Essen, Germany, Essen, Germany
¹⁴Medizinische Klinik m. S. Hämatologie , Onkologie und Tumorimmunologie, Berlin, Germany, Berlin, Germany
¹⁵University Hospital Eppendorf, Hamburg, Germany, Hamburg, Germany
¹⁶HUCH Comprehensive Cancer Center, Helsinki, Finland, Helsinki, Finland
¹⁷Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, Vilnius, Lithuania
¹⁸Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
¹⁹Hematology and Bone Marrow transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Milano, Italy
²⁰Hematology Department, Hospital Universitari i Politècnic La Fe, Departament de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, Spain, VALENCIA, Spain
²¹American University of Beirut Dept. of Medicine, Beirut, Lebanon
²²Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv, Israel
²³Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France
²⁴Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France
²⁵Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. San Raffaele Scientific Institute, Milan, Italy

5:15 PM

694

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Caspian H. Oliai, MD¹, Rasmus T. Hoeg, MD²^*, Arpita Gandhi, MD³, Lori Muffly, MD⁴, Samer A. Srour, MD⁵, Rohtesh S. Mehta, MD, MPH⁵^*, Edmund K. Waller, MD, PhD⁶, Robert Lowsky, MD⁴^*, Sagar S. Patel, MD⁷, Bhagirathbhai R. Dholaria, MBBS⁸, Jeremy Pantin, MD⁹, Amandeep Salhotra, MD¹⁰, Joseph P. McGuirk, DO¹¹, Steven Michael Devine, MD¹², Alexandra Gomez-Arteaga, MD¹³^*, Rawan Faramand, MD¹⁴, Roni Tamari, MD¹⁵, Jennifer L Holter-Chakrabarty, MD¹⁶, Betty K. Hamilton, MD¹⁷, Antonio M. Jimenez Jimenez, MD, MSc¹⁸^*, Anna Pavlova, MD, PhD¹⁹, Nathaniel B. Fernhoff, PhD¹⁹^*, J. Scott McClellan, MD, PhD¹⁹, Mehrdad Abedi, MD²^*, Robert S. Negrin, MD²⁰ and Everett H. Meyer, MD, PhD⁴

¹Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA
²Comprehensive Cancer Center, University of California, Davis, Sacramento, CA
³Knight Cancer Institute, Oregon Health & Science University, Portland, OR
⁴Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
⁵Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Emory University, Winship Cancer Institute, Atlanta, GA
⁷Transplant and Cellular Therapy Program, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
⁸Vanderbilt University Medical Center, Nashville, TN
⁹Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, Nashville, TN
¹⁰Hematology and HCT, City of Hope National Medical Center, Duarte, CA
¹¹Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Ctr., Westwood, KS
¹²Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN
¹³Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY
¹⁴Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁵Department of Medicine, Weill Cornell Medicine, New York, NY
¹⁶University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK
¹⁷Cleveland Clinic Foundation, Cleveland, OH
¹⁸Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, FL
¹⁹Orca Bio, Menlo Park, CA
²⁰Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA

5:30 PM

695

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Stephanie J. Lee, MD, MPH¹, Brent R. Logan, PhD²^*, Mary M. Horowitz, MD^2,3, Peter Westervelt, MD⁴, William J. Hogan, MD⁵, Joseph A. Pidala, MD, PhD⁶, Jason Dehn, MPH⁷^*, Brandon Hayes-Lattin, MD⁸, Nosha Farhadfar, MD⁹^*, Asad Bashey, MD, PhD¹⁰, Michael R. Grunwald, MD¹¹, Samer A. Srour, MD¹², Claudio Brunstein, MD, PhD¹³, Heather Jill Symons, MD¹⁴^*, Joseph Uberti, MD, PhD¹⁵, Iskra Pusic, MD⁴, Eric Leifer, PhD¹⁶^*, Naya He¹⁷^*, Steven Michael Devine, MD¹⁸, Bronwen E. Shaw, MD, PhD¹⁹ and Stefan O. Ciurea, MD²⁰

¹Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
²Medical College of Wisconsin, Milwaukee, WI
³Center for International Blood and Marrow Transplant Research (CIBMTR), Minneapolis, MN
⁴Division of Oncology, Washington University School of Medicine, Saint Louis, MO
⁵Division of Hematology, Mayo Clinic, Rochester, MN
⁶Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁷Minneapolis, Minneapolis, MN
⁸Knight Cancer Institute, Oregon Health & Science University, Portland, OR
⁹University of Florida, Gainesville, FL
¹⁰BMT Program at Northside Hospital, Atlanta, GA
¹¹Levine Cancer Institute, Charlotte
¹²Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹³Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
¹⁴Johns Hopkins Hospital, Baltimore, MD
¹⁵Karmanos Cancer Institute, Detroit, MI
¹⁶National Heart Lung and Blood Institute, Bethesda, MD
¹⁷Center for International Blood and Marrow Transplant Research, Milwaukee, WI
¹⁸Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN
¹⁹CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
²⁰MD Anderson Cancer Center, Irvine, CA

5:45 PM

696

Haploidentical Peripheral Blood Stem Cell Combined with Bone Marrow or Unrelated Cord Blood As Grafts for Acute Leukemia/Myelodysplastic Syndrome: An Open-Label, Multicenter, Randomized, Phase 3 Trial

Sijian Yu¹^* and Fen Huang²^*

¹Nanfang Hospital,Southern Medical University, Guangzhou, China
²Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

732.Oral Section I 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA